NSPX

Inspyr Therapeutics (PK) Stock Price

0.01755
-0.00145 (-7.63%)
0.01755
Best deals to access real time data!
Small Cap Basic
Monthly Subscription
for only
$33.03
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
VAT not included
Company Name Stock Ticker Symbol Market Type
Inspyr Therapeutics Inc (PK) NSPX OTCMarkets Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.00145 -7.63% 0.01755 16:00:05
Open Price Low Price High Price Close Price Prev Close
0.0185 0.0162 0.019 0.01755 0.019
Bid Price Ask Price Spread News
0.0175 0.0178 0.0003 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
203 7,095,798 $ 0.017471 $ 123,974 - 0.0005 - 0.0718
Last Trade Time Type Quantity Stock Price Currency
15:59:58 7,400 $ 0.01755 USD

Inspyr Therapeutics (PK) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 2.63M 150.00M - $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
158.39k $ - 0.00% - -

more financials information »

Inspyr Therapeutics (PK) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical NSPX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.020.0230.01620.020113810,422,263-0.00245-12.25%
1 Month0.00840.0570.00680.02259933,444,7030.00915108.93%
3 Months0.00940.0570.0040.015551620,866,0370.0081586.7%
6 Months0.020.07180.00050.019889317,935,582-0.00245-12.25%
1 Year0.00290.07180.00050.017540814,603,5870.01465505.17%
3 Years0.03380.07180.00050.01512356,295,034-0.01625-48.08%
5 Years0.135054.990.00050.01543573,805,044-0.1175-87.0%

Inspyr Therapeutics (PK) Description

Inspyr Therapeutics develops curative cancer therapies that are core to the principles of finding the best way to cure or extend human life. Its innovative approach to drug delivery is expected to maximize anti-tumor activity while minimizing side effects. Inspyr's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of the company's drug candidates within a tumor. Inspyr's lead drug candidate, mipsagargin, is activated by the enzyme PSMA, which is found at high levels in the blood vessels of liver and glioblastoma cancers and in the blood vessels of almost all other solid tumors. Mipsagargin is expected to have potential efficacy in a wide variety of tumor types.


Your Recent History
USOTC
NSPX
Inspyr The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.